TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19918201

Group type: EXPERIMENTAL
Intervention: Near-infrared tissue spectrometer InSpectra (Hutchinson Technology Inc.) measuring StO2 on bicep muscle
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Near-infrared tissue spectrometer InSpectra (Hutchinson Technology Inc.) measuring StO2 on deltoid muscle
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Near-infrared tissue spectrometer InSpectra (Hutchinson Technology Inc.) measuring StO2 on thenar eminence
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Near-infrared tissue spectrometer InSpectra (Hutchinson Technology Inc.) measuring StO2 on other areas (forearm, calf, tricep)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Near-infrared tissue spectrometer InSpectra (Hutchinson Technology Inc.) measuring StO2
Number of subjects: 310
Study: 17365773

Group type: EXPERIMENTAL
Intervention: Interactive Internet sites (highly utilized)
Number of subjects: 6451

Group type: EXPERIMENTAL
Intervention: Interactive Internet sites (less utilized)
Number of subjects: 6451

Group type: COMPARATOR
Intervention: Static Internet site with quitting advice
Number of subjects: 6451
Study: 16332600

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5FU/levamisole for 12 months, n = 444; 5FU/leucovorin for 4-5 months, n = 262; 5FU/leucovorin with +/- levamisole, n = 397)
Number of subjects: 2224

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 2224
Study: 12006716

Group type: EXPERIMENTAL
Intervention: Intranasal buserelin acetate 300 microg 6 times daily for 2 years
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Subcutaneous Suprefact Depot 6.3 mg every 8 weeks for the third year
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment in addition to pubertal inhibition (randomized in half of the girls)
Number of subjects: 46
Study: 9864110

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (laparoscopic procedure)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 32
Study: 7615321

Group type: EXPERIMENTAL
Intervention: Ovoid bars with a resilient joint
Number of subjects: 2

Group type: COMPARATOR
Intervention: Parallel-sided bars with a rigid joint
Number of subjects: 2
Study: 2117205

Group type: EXPERIMENTAL
Intervention: Bovine surfactant (SF‐RI 1)
Number of subjects: 0
Study: 728283

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (10 mg)
Number of subjects: 7
Study: 31754964

Group type: EXPERIMENTAL
Intervention: Immediate group (n=17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waitlist group (n=17)
Number of subjects: 34
Study: 30472901

Group type: EXPERIMENTAL
Intervention: Experimental group (EXPg) using brain-sensing devices
Number of subjects: 55

Group type: COMPARATOR
Intervention: Active control group (CONTg)
Number of subjects: 55
Study: 27589411

Group type: EXPERIMENTAL
Intervention: Permissive underfeeding with full protein intake
Number of subjects: 894

Group type: COMPARATOR
Intervention: Standard feeding
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 894
Study: 24887970

Group type: EXPERIMENTAL
Intervention: Video-based peer feedback through social networking
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no peer feedback)
Number of subjects: 41
Study: 25276712

Group type: EXPERIMENTAL
Intervention: Educational and modifying intervention about asthma triggers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 21383359

Group type: EXPERIMENTAL
Intervention: GRACE intervention (in-home assessments by a nurse practitioner and a social worker)
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: GRACE intervention
Number of subjects: 951

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 951
Study: 19951217

Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 126
Study: 18018467

Group type: EXPERIMENTAL
Intervention: Scaling and root planning plus systematic use of doxycycline
Number of subjects: 46
Study: 15159227

Group type: EXPERIMENTAL
Intervention: Moderate n-6 PUFA diet + 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High n-6 PUFA diet + 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid) after 6 weeks of dietary intervention
Number of subjects: 29
Study: 11953878

Group type: EXPERIMENTAL
Intervention: 600 mg intravenous clodronate
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 900 mg intravenous clodronate
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 1200 mg intravenous clodronate
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 1500 mg intravenous clodronate
Number of subjects: 86
Study: 9797079

Group type: EXPERIMENTAL
Intervention: CD45-negative B-cell precursor ALL
Number of subjects: 638

Group type: COMPARATOR
Intervention: CD45-positive B-cell precursor ALL
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: CD45-negative subpopulation
Number of subjects: 638
Study: 7639232

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 2146057

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg every 12 hours)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg every 8 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (every 12 hours)
Number of subjects: 18
Study: 369651

Group type: EXPERIMENTAL
Intervention: Acarbose (alpha-glucosidehydrolase inhibitor) taken with food
Number of subjects: 7

Group type: COMPARATOR
Intervention: Dummy tablets (control)
Number of subjects: 7
Study: 30986302

Group type: EXPERIMENTAL
Intervention: Intranasal administration of 16.1 mg of ASAL‐HM
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intranasal administration of 8.0 mg of HM (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intranasal administration of ASAL‐HM
Number of subjects: 26
Study: 31829233

Group type: EXPERIMENTAL
Intervention: Budget tool developed by KCE Trials programme
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Risk-reducing measures (multistep selection process, advance payments, recruitment feasibility check, close monitoring, milestone-based payment schedule)
Number of subjects: 17
Study: 30055692

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection with 40 mg triamcinolone acetonide
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Intravitreal injection with 1.25 mg bevacizumab
Number of subjects: 213

Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Combination of subconjunctival triamcinolone acetonide and intravitreal bevacizumab
Number of subjects: 213
Study: 27817811

Group type: EXPERIMENTAL
Intervention: GFF MDI 18/9.6 μg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: GFF MDI 9/9.6 μg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: GFF MDI 4.6/9.6 μg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: GFF MDI 2.4/9.6 μg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: GFF MDI 1.2/9.6 μg
Number of subjects: 159

Group type: COMPARATOR
Intervention: GP MDI 18 μg
Number of subjects: 159

Group type: COMPARATOR
Intervention: FF MDI 9.6 μg
Number of subjects: 159

Group type: COMPARATOR
Intervention: Open-label tiotropium 18 μg
Number of subjects: 159
Study: 24918880

Group type: EXPERIMENTAL
Intervention: Thermal mattress
Number of subjects: 38

Group type: COMPARATOR
Intervention: Thermal blanket
Number of subjects: 38
Study: 22301084

Group type: EXPERIMENTAL
Intervention: Buprenorphine induction for heroin users
Number of subjects: 228

Group type: COMPARATOR
Intervention: Buprenorphine induction for prescription opioid users
Number of subjects: 228
Study: 19330802

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17502270

Group type: EXPERIMENTAL
Intervention: BRP analysis
Number of subjects: 1552

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 1552
Study: 15140330

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25mg
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50mg
Number of subjects: 690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Rofecoxib (both dosages)
Number of subjects: 690
Study: 11419425

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 4809

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 4809
Study: 10436979

Group type: EXPERIMENTAL
Intervention: Zhuling polysaccharides combined with hepatitis B vaccine (group I)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: LAK cells induced by interleukin‐2 (IL‐2) transfusion therapy (group II)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Bacille Calmette‐Guerin (BCG) combined with persatin (group III)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Interferon (control group)
Number of subjects: 286

Group type: COMPARATOR
Intervention: 10% glucose (control group)
Number of subjects: 286
Study: 8177016

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 9
Study: 3065667

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 24
Study: 31734931

Group type: EXPERIMENTAL
Intervention: Drama mode of school dental health education (SDHE)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Modified snake and ladder game mode of SDHE
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Flashcard mode of SDHE
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: All modes of SDHE
Number of subjects: 360
Study: 29279299

Group type: EXPERIMENTAL
Intervention: Intensive glycemic therapy (target HbA1c <6.0%)
Number of subjects: 10251
Study: 27494777

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 4 weeks for ≤7.5 years
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group (without early remission)
Number of subjects: 390
Study: 24728846

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 6000 impulses (energy flux density, 0.11 mJ/mm²) in three sessions after local anesthesia.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group - 6000 impulses of sham ESWT after local anesthesia.
Number of subjects: 0
Study: 23491820

Group type: EXPERIMENTAL
Intervention: Multiple tailoring and counseling
Number of subjects: 414

Group type: COMPARATOR
Intervention: Multiple tailoring only
Number of subjects: 414

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 414
Study: 19962288

Group type: EXPERIMENTAL
Intervention: Silexan (lavender oil preparation), 6-week intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorazepam (benzodiazepine), 6-week intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silexan and Lorazepam
Number of subjects: 0
Study: 18541280

Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg bid for 3 days
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Tafenoquine 400 mg od for 3 days
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Primaquine plus doxycycline (22.5 mg + 100 mg daily for 14 days)
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg od for 3 days
Number of subjects: 1512
Study: 15645413

Group type: EXPERIMENTAL
Intervention: Recording from flexor carpi ulnaris
Number of subjects: 17

Group type: COMPARATOR
Intervention: Recording from abductor digiti minimi
Number of subjects: 17
Study: 12820077

Group type: EXPERIMENTAL
Intervention: Nursing literature reading course
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no course)
Number of subjects: 170
Study: 10998316

Group type: EXPERIMENTAL
Intervention: RSV inoculation (approximately 10^3 plaque‐forming units)
Number of subjects: 10
Study: 8869096

Group type: EXPERIMENTAL
Intervention: Supportive care plus MLT (20 mg/day orally in the evening)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 100
Study: 8465554

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (S.b.) 250 mg t.i.d. for 7 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2871081

Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) irradiation during surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional ventilation without UV irradiation
Number of subjects: 30
Study: 30526587

Group type: EXPERIMENTAL
Intervention: Suction-stylet
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Suction-no stylet
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Stylet-no suction
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Suction
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: No stylet
Number of subjects: 97

Group type: COMPARATOR
Intervention: All procedures
Number of subjects: 97
Study: 27376907

Group type: EXPERIMENTAL
Intervention: Lidocaine gel (10 ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline solution (10 ml)
Number of subjects: 100
Study: 25940250

Group type: EXPERIMENTAL
Intervention: Predischarge bundle intervention including smoking cessation counseling, screening for gastroesophageal reflux disease and depression or anxiety, standardized inhaler education, and a 48-h postdischarge telephone call.
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both groups (bundle and control).
Number of subjects: 172
Study: 24265523

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 850
Study: 21615492

Group type: EXPERIMENTAL
Intervention: Melatonin supplementation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 2
Study: 19274410

Group type: EXPERIMENTAL
Intervention: Cooperflex (Cooper Vision)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Frequency(R) 55 Aspheric (Cooper Vision)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: World Vision FW (World Vision)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pure Vision (Bausch & Lomb)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Focus Monthly (Ciba Vision)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Focus Choice AB (Ciba Vision)
Number of subjects: 130
Study: 17146319

Group type: EXPERIMENTAL
Intervention: IV rehydration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ORAL rehydration
Number of subjects: 8
Study: 12700305

Group type: EXPERIMENTAL
Intervention: Light Touch (LT; <1 N)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Heavy Touch (HT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No Fingertip Touch (NT)
Number of subjects: 18
Study: 10924977

Group type: EXPERIMENTAL
Intervention: Conventionally fractionated (cf) treatment: 60 Gy over 6 weeks (n = 79)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Palliative accelerated irradiation regimen (PAIR): 32 Gy, 2 Gy b.i.d. (n = 73)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 152
Study: 8738054

Group type: EXPERIMENTAL
Intervention: alfuzosin
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 260

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 260
Study: 1405361

Group type: EXPERIMENTAL
Intervention: Treatment of hypertension to blood pressure values within the normal range
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-protein diets with ketoacid supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment of hyperlipidemia
Number of subjects: 0
Study: 3902908

Group type: EXPERIMENTAL
Intervention: Listerine antiseptic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 0
Study: 31197986

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 conjugate vaccine
Number of subjects: 64

Group type: COMPARATOR
Intervention: MenACWY-DT conjugate vaccine
Number of subjects: 64
Study: 29100777

Group type: EXPERIMENTAL
Intervention: Tibial tubercle lateralization with TT-TG distance of 20 mm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Patella alta with Caton-Deschamps Index (CDI) of 1.2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of tibial tubercle lateralization and patella alta
Number of subjects: 9
Study: 27358434

Group type: EXPERIMENTAL
Intervention: High-dose edoxaban regimen (HDER) 60 mg daily or 30 mg daily for CrCl 30-50 mL/min
Number of subjects: 14071

Group type: EXPERIMENTAL
Intervention: High-dose edoxaban regimen (HDER)
Number of subjects: 14071

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14071
Study: 24516103

Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitagliptin with Enalaprilat
Number of subjects: 12
Study: 21679921

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 211

Group type: COMPARATOR
Intervention: Emergency portacaval shunt
Number of subjects: 211
Study: 20438400

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.033 mg/kg/day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.067 mg/kg/day
Number of subjects: 79
Study: 17063357

Group type: EXPERIMENTAL
Intervention: Prototype device for maintaining constant endotracheal cuff pressure (Pcuff)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control day with manometer monitoring and adjusting Pcuff
Number of subjects: 9
Study: 16283123

Group type: EXPERIMENTAL
Intervention: Standardized diagnostic assessment including self-reporting, clinical interview, and laboratory measures.
Number of subjects: 55118

Group type: EXPERIMENTAL
Intervention: Extensive standardized laboratory screening program and 12-month follow-up investigation.
Number of subjects: 55118
Study: 11838724

Group type: EXPERIMENTAL
Intervention: Expert group (viewed 4 translated educational videotapes about pain management)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nonexpert group (received no pain education)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Expert group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nonexpert group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Entire sample (n = 30)
Number of subjects: 46
Study: 12016800

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5‐7.5 mg.d‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dihydro-chlorothiazide (50‐70 mg.d‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbamazepine (150‐300 mg.d‐1)
Number of subjects: 8
Study: 8824659

Group type: EXPERIMENTAL
Intervention: Polyunsaturated phosphatidyl choline (900 mg orally daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study: 1614464

Group type: EXPERIMENTAL
Intervention: Standard immune globulin (400 mg per kilogram of body weight)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Core-lipopolysaccharide hyperimmune globulin (400 mg per kilogram)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo (25 percent albumin, 8 ml per kilogram)
Number of subjects: 352
Study: 6584446

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CuSO4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 0
Study: 30507280

Group type: EXPERIMENTAL
Intervention: Structured exercise (treadmill walking)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No structured exercise
Number of subjects: 51
Study: 29288775

Group type: EXPERIMENTAL
Intervention: polihexanide 0.04%
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ringer solution
Number of subjects: 61
Study: 26852095

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) combined with maintenance antidepressant medication (mADM)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Maintenance antidepressant medication (mADM)
Number of subjects: 317
Study: 25315287

Group type: EXPERIMENTAL
Intervention: Optimising TB/HIV service integration intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 22386385

Group type: EXPERIMENTAL
Intervention: Preoperative duplex vein mapping (DVM)
Number of subjects: 130

Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 130
Study: 19671565

Group type: EXPERIMENTAL
Intervention: Injection Troynoxa (enoxaparin sodium 40 mg/0.4 mL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Injection Clexane (enoxaparin sodium 40 mg/0.4 mL)
Number of subjects: 12
Study: 17267793

Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 15958318

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study: 12190161

Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg <70 kg b.w. or 3 mg >70 kg b.w.) and propofol (median dose 80 mg, range 40-150)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Midazolam (median dose 5 mg, range 3-7) and pethidine (75 mg, range 50-125)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam and propofol
Number of subjects: 120
Study: 9973029

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with heparin (5,000 U bolus, 1,000 to 1,300 U/h infusion)
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with hirudin (0.1 to 0.6 mg/kg bolus, 0.1 to 0.2 mg/kg/h infusion)
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Age >70 years
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Prior angina
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Age >70 years (nonrupture death)
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Prior MI (nonrupture death)
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Intensity of anticoagulation (heparin or hirudin)
Number of subjects: 3759